EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
MAR 2023
TABLES
123
PAGES
193
EDITION
7
PRICE
USD 5450
CODE
MCP12245
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Gynecological Cancer Drugs Market to Reach $21.5 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Gynecological Cancer Drugs estimated at US$14.4 Billion in the year 2022, is projected to reach a revised size of US$21.5 Billion by 2030, growing at aCAGR of 5.2% over the period 2022-2030. Targeted Therapy, one of the segments analyzed in the report, is projected to record 5.6% CAGR and reach US$10.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chemotherapy segment is readjusted to a revised 5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $4.3 Billion, While China is Forecast to Grow at 4.8% CAGR
The Gynecological Cancer Drugs market in the U.S. is estimated at US$4.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
SELECT PLAYERS
AstraZeneca PLC; Bristol-Myers Squibb Company; Dr. Reddy's Laboratories Ltd.; Eli Lilly and Company; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Pfizer, Inc.; Sanofi SA; Takeda Pharmaceutical Co., Ltd.
SEGMENTS
» Therapeutic Modality (Targeted Therapy, Chemotherapy, Hormonal Therapy) » Indication (Cervical Cancer, Uterine Cancer, Ovarian Cancer, Vaginal & Vulvar Cancer)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
Gynaecological Cancer Drugs – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Cervical Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Uterine Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Uterine Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Uterine Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Gynecological Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
World Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Gynecological Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Gynecological Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Vaginal & Vulvar Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Vaginal & Vulvar Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Vaginal & Vulvar Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
USA Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
USA Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
CANADA |
Canada Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
Canada Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
JAPAN |
Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
Japan Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
Japan Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
CHINA |
Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
China Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
China Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
EUROPE |
Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Gynecological Cancer Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Gynecological Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
FRANCE |
Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
France Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
France Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
GERMANY |
Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
Germany Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
Germany Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
ITALY |
Italy Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
Italy Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
UNITED KINGDOM |
Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
UK Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
UK Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
Rest of Europe Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
ASIA-PACIFIC |
Gynecological Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Gynecological Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Gynecological Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Cervical Cancer, Uterine Cancer, Ovarian Cancer and Vaginal & Vulvar Cancer for the Years 2012, 2021 & 2027 |
Rest of World Recent Past, Current & Future Analysis for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Gynecological Cancer Drugs by Therapeutic Modality - Targeted Therapy, Chemotherapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Gynecological Cancer Drugs by Therapeutic Modality - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Hormonal Therapy for the Years 2012, 2021 & 2027 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com